deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT02699645

Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT)

Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT), Substudies: MRI, Cognitive

Sponsor: The George Institute

Conditions Hypertension Intracerebral Haemorrhage (ICH)
Interventions Placebo telmisartan 20mg, amlodipine 2.5mg, and indapamide 1.25mg
Updated 21 times since 2017 Last updated: Sep 7, 2025 Started: Sep 28, 2017 Primary completion: Aug 27, 2025 Completion: Aug 27, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02699645, this PHASE3 trial focuses on Hypertension and Intracerebral Haemorrhage (ICH) and remains completed. Sponsored by The George Institute, it has been updated 21 times since 2017, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jul 2017 · 5 months · monthly snapshot~Jul 2017 – ~Oct 2017 · 3 months · monthly snapshot~Oct 2017 – ~Mar 2018 · 5 months · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshot~Nov 2018 – ~Aug 2019 · 9 months · monthly snapshot~Aug 2019 – ~Mar 2020 · 7 months · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Jul 2020 · 2 months · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Oct 2020 · 2 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~May 2024 · 32 months · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – present · 9 months · monthly snapshot

Change History

21 versions recorded

  1. Oct 2025 — Present [monthly]

    Completed PHASE3

    Status: Recruiting → Completed

  2. Sep 2025 — Oct 2025 [monthly]

    Recruiting PHASE3

  3. Sep 2024 — Sep 2025 [monthly]

    Recruiting PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE3

  5. May 2024 — Jul 2024 [monthly]

    Recruiting PHASE3

▶ Show 16 earlier versions

  1. Sep 2021 — May 2024 [monthly]

    Recruiting PHASE3

  2. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE3

  3. Oct 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

  4. Aug 2020 — Oct 2020 [monthly]

    Recruiting PHASE3

  5. Jul 2020 — Aug 2020 [monthly]

    Recruiting PHASE3

  6. May 2020 — Jul 2020 [monthly]

    Recruiting PHASE3

  7. Apr 2020 — May 2020 [monthly]

    Recruiting PHASE3

  8. Mar 2020 — Apr 2020 [monthly]

    Recruiting PHASE3

  9. Aug 2019 — Mar 2020 [monthly]

    Recruiting PHASE3

  10. Nov 2018 — Aug 2019 [monthly]

    Recruiting PHASE3

    Phase: PHASE4 → PHASE3

  11. Jun 2018 — Nov 2018 [monthly]

    Recruiting PHASE4

  12. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE4

  13. Oct 2017 — Mar 2018 [monthly]

    Recruiting PHASE4

    Status: Not Yet Recruiting → Recruiting

  14. Jul 2017 — Oct 2017 [monthly]

    Not Yet Recruiting PHASE4

  15. Feb 2017 — Jul 2017 [monthly]

    Not Yet Recruiting PHASE4

  16. Jan 2017 — Feb 2017 [monthly]

    Not Yet Recruiting PHASE4

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • The George Institute
  • The University of New South Wales
Data source: The George Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Birtinya, Australia , Botucatu, Brazil , Chiayi City, Taiwan , Colombo, Sri Lanka , Curitiba, Brazil , Edinburgh, United Kingdom , Exeter, United Kingdom , Fortaleza, Brazil , Galle, Sri Lanka , Gampaha, Sri Lanka and 42 more locations